Adverse effects of vitamin E by induction of drug metabolism

被引:41
作者
Brigelius-Flohe, Regina [1 ]
机构
[1] German Inst Human Nutr Potsdam Rehbrucke, Dept Biochem Micronutrients, D-14558 Nuthetal, Germany
关键词
vitamin E; clinical trial; cardiovascular disease; drug metabolism; interference with drug metabolism; adverse effects;
D O I
10.1007/s12263-007-0055-0
中图分类号
Q3 [遗传学];
学科分类号
071007 [遗传学]; 090102 [作物遗传育种];
摘要
Observational studies with healthy persons demonstrated an inverse association of vitamin E with the risk of coronary heart disease or cancer, the outcome of large-scale clinical trials conducted to prove a benefit of vitamin E in the recurrence and/or progression of such disease, however, was disappointing. Vitamin E did not provide benefits to patients with cardiovascular diseases, cancer, diabetes or hypertension. Even harmful events and worsening of pre-existing diseases were reported, which are hard to explain. Since vitamin E is metabolized along the same routes as xenobiotics and induces drug-metabolizing enzymes in rodents, it is hypothesized that a supplementation with high dosages of vitamin E may also lead to an induction of the drug-metabolizing system in patients that depend on drug therapy. Compromising essential therapy might therefore outweigh any benefit of vitamin E in patients. It is recommended to work out at which threshold the drug-metabolizing system can be induced in humans before new trials with high dosages of vitamin E are started.
引用
收藏
页码:249 / 256
页数:8
相关论文
共 80 条
[1]
Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
[2]
Effect of 1-year oral α-tocopherol administration on anticardiolipin antibodies in hemodialysis patients [J].
Antoniadi, G ;
Eleftheriadis, T ;
Liakopoulos, V ;
Kakasi, E ;
Vayonas, G ;
Kortsaris, A ;
Vargemezis, V .
RENAL FAILURE, 2005, 27 (02) :193-198
[3]
Baggott JE, 2005, ANN INTERN MED, V143, P155, DOI 10.7326/0003-4819-143-2-200507190-00028
[4]
Identities and differences in the metabolism of tocotrienols and tocopherols in HepG2 cells [J].
Birringer, M ;
Pfluger, P ;
Kluth, D ;
Landes, N ;
Brigelius-Flohé, R .
JOURNAL OF NUTRITION, 2002, 132 (10) :3113-3118
[5]
Tocopherols are metabolized in HepG2 cells by side chain ω-oxidation and consecutive β-oxidation [J].
Birringer, M ;
Drogan, D ;
Brigelius-Flohe, R .
FREE RADICAL BIOLOGY AND MEDICINE, 2001, 31 (02) :226-232
[6]
Antioxidant supplements for prevention of gastrointestinal cancers: a systematic review and meta-analysis [J].
Bjelakovic, G ;
Nikolova, D ;
Simonetti, RG ;
Gluud, C .
LANCET, 2004, 364 (9441) :1219-1228
[7]
Mortality in randomized trials of antioxidant supplements for primary and secondary prevention - Systematic review and meta-analysis [J].
Bjelakovic, Goran ;
Nikolova, Dimitrinka ;
Gluud, Lise Lotte ;
Simonetti, Rosa G. ;
Gluud, Christian .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 297 (08) :842-857
[8]
Blatt DH, 2005, ANN INTERN MED, V143, P150, DOI 10.7326/0003-4819-143-2-200507190-00018
[9]
NUTRITION INTERVENTION TRIALS IN LINXIAN, CHINA - SUPPLEMENTATION WITH SPECIFIC VITAMIN MINERAL COMBINATIONS, CANCER INCIDENCE, AND DISEASE-SPECIFIC MORTALITY IN THE GENERAL-POPULATION [J].
BLOT, WJ ;
LI, JY ;
TAYLOR, PR ;
GUO, WD ;
DAWSEY, S ;
WANG, GQ ;
YANG, CS ;
ZHENG, SF ;
GAIL, M ;
LI, GY ;
YU, Y ;
LIU, BQ ;
TANGREA, J ;
SUN, YH ;
LIU, FS ;
FRAUMENI, JF ;
ZHANG, YH ;
LI, B .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (18) :1483-1492
[10]
Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial [J].
Boaz, M ;
Smetana, S ;
Weinstein, T ;
Matas, Z ;
Gafter, U ;
Iaina, A ;
Knecht, A ;
Weissgarten, Y ;
Brunner, D ;
Fainaru, M ;
Green, MS .
LANCET, 2000, 356 (9237) :1213-1218